logoInnovations in Non-Invasive Stone Treatment

Each year, more than three million Americans see a physician for kidney stones and over 700,000 procedures are performed to break large kidney stones.
SonoMotion is developing non-invasive solutions for kidney stone disease with two breakthrough products:
  • Break WaveTM will fragment large kidney stones faster, safer and more effectively than existing options.
  • Stone ClearTM, which is currently in clinical trials, will help clear the resulting stone fragments within 15 minutes in an office setting and also without general anesthesia or x-ray radiation.
    • November 7th, 2019

      SonoMotion closes $10M Series-B round co-led by Advance MedTech Holdings Pte. Ltd., MedVenture Partners Inc and BioVentures. Link to press release.

  • August 20th, 2019

    SonoMotion initiates First-In-Human clinical trial of its Break WaveTM stone fragmentation system

  • May 1st, 2019

    SonoMotion secures a $3M SBIR Phase IIB grant from the NIH in support of its Break WaveTM First-In-Human clinical trial. Planned sites include UW, UBC, UCSD, Cleveland Clinic and Chesapeake Urology.

  • March 28th, 2019

    GE Healthcare and SonoMotion sign a second co-development agreement and expand their strategic relationship with an updated OEM agreement.

  • March 26th, 2019

    SonoMotion receives Health Canada ITA approval to initiate its Break WaveTM First-In-Human clinical trial in Canada.

  • December 14th, 2018

    SonoMotion receives FDA IDE approval to initiate its Break WaveTM First-In-Human clinical trial in the Unites States.

  • October 31st, 2017

    GE Healthcare and SonoMotion establish a strategic partnership and sign a definitive OEM agreement and co-development agreement.

  • August 1st, 2017

    SonoMotion receives a $1.0M SBIR Commercial Readiness Program grant from the NIH for the development of Stone ClearTM.

  • April 7th, 2017

    SonoMotion closes on a $4.6M Series-A round led by MedVenture Partners Inc. and with a significant participation by Bioventures Investors.

  • May 1st, 2016

    SonoMotion secures a $1.75M SBIR FastTrack grant from the NIH for the development of Break WaveTM.

  • April 1st, 2016

    SonoMotion receives a $350,000 grant from NASA and NSBRI to accelerate development of Break WaveTM.

  • December 2nd, 2015

    SonoMotion wins Runner-Up and $50,000 in the prestigious primeUC life science startup competition organized by the University of California and Johnson & Johnson.

  • September 7th, 2015

    Dr. Doug Corl joins SonoMotion as its Chief Technology Officer bringing over 35 years of experience in developing commercial ultrasound-based medical devices.

  • August 1st, 2015

    SonoMotion secures a $1.75M non-dilutive SBIR grant funding from the NIH for the development of Stone ClearTM

  • Jan 11th, 2015

    SonoMotion reaches agreement with the University of Washington for exclusive license to an extensive IP portfolio related to Break WaveTM and Stone ClearTM.

  • May 19th, 2015

    Positive First-In-Man Stone ClearTM clinical trial results presented at the American Urological Association (AUA) meeting in New Orleans.

  • October 24th, 2014

    SonoMotion brings onboard Dr. Oren Levy as its Chief Executive Officer and Chairman of the Board.

  1. Fragmentation of Urinary Calculi In Vitro by Burst Wave Lithotripsy

    Maxwell AD, Cunitz BW, Kreider W, Sapozhnikov O, Hsi RS, Harper JD, Bailey MR, Sorensen MD. J Urol. 2015 Jan;193(1):338-44

  2. Bursting through limitations of SWL

    Thoma C. Nat Rev Urol. 2014 Oct;11(10):540

  3. Combined Burst Wave Lithotripsy and Ultrasonic Propulsion for Improved Urinary Stone Fragmentation

    Zwaschka TA, Ahn JS, Cunitz BW, Bailey MR, Dunmire B, Sorensen MD, Harper JD, Maxwell AD. J Endourol. 2018 Apr;32(4):344-349

  4. Detection and Evaluation of Renal Injury in Burst Wave Lithotripsy Using Ultrasound and Magnetic Resonance Imaging

    May PC, Kreider W, Maxwell AD, Wang YN, Cunitz BW, Blomgren PM, Johnson CD, Park JSH, Bailey MR, Lee D, Harper JD, Sorensen MD. J Endourol. 2017 Aug;31(8):786-792

  5. First-in-human feasibility trial for ultrasonic propulsion of kidney stones

    Harper JD, Cunitz BW, Dunmire B, Lee FC, Sorensen MD, Hsi RS, Thiel J, Wessells H, Lingeman JE, Bailey MR. J Urol. 2016 Apr;195(4):956-964

  6. Ultrasonic propulsion of kidney stones – Review

    May PC, Bailey MR, Harper JD. Curr Opin Urol. 2016 May;26(3):264-70

  7. Preclinical safety and effectiveness studies of ultrasonic propulsion of kidney stones

    Harper JD, Dunmire B, Wang YN, Simon JC, Liggitt D, Paun M, Cunitz BW, Starr F, Bailey MR, Penniston KL, Lee FC, Hsi RS, Sorensen MD. Urology. 2014 Aug;84(2):484-9

  8. Use of the acoustic shadow width to determine kidney stone size with ultrasound

    Dunmire B, Harper JD, Cunitz BW, Lee FC, Hsi R, Liu Z, Bailey MR, Sorensen MD. J Urol. 2016 Jan;195(1):171-7

  9. Improved detection of kidney stones using an optimized Doppler imaging sequence

    Cunitz B, Dunmire B, Paun M, Sapozhnikov O, Kucewicz J, Hsi R, Lee F, Sorensen M, Harper J, Bailey M. IEEE Int Ultrason Symp. 2014 Sep 3;2014:452-455

  • Oren Levy, PhD

    Chief Executive Officer
    Dr. Oren Levy is an experienced medical device leader and entrepreneur with an outstanding record of achievement. Dr. Levy played a key role in the management and acquisition of Fluid Medical, an ultrasound based medical device startup, by Volcano Corporation (acquired by Philips). Dr. Levy has led and managed multi-disciplinary teams including disposable, hardware and software R&D and product marketing in both large-company and entrepreneurial environments. Dr. Levy integrates a personal background in science, operations and management consulting to introduce structure and rigor to a start-up environment. Most recently, Dr. Levy led Volcano Corporation’s Mountain View office with $3.4M annual budget supervising an eleven person team developing a percutaneous forward looking intra‐cardiac ultrasound imaging device. Dr. Levy received a PhD in Biophysics and a double BA degree in Physics and Astrophysics from UC Berkeley.

  • Doug Corl, PhD

    Chief Technology Officer
    Dr. Corl is a proven and recognized ultrasound expert with over 35 years of experience in developing and delivering commercial ultrasound-based medical devices. Dr. Corl has 38 issued patents and was either the CTO or Chief Scientist for the past 24 years at both early stage startups and large multinational ultrasound-based companies, including Volcano Corporation, Keimar, PharmaSonics and Cardiometrics. Dr. Corl received a PhD in Electrical Engineering from Stanford University and a BA and MS in Electrical Engineering from UC Irvine.

Dr. James Lingeman, MD
Indiana University
Professor of Urology and past President of the Endourological Society
Dr. Mathew Sorensen, MD, MS
University of Washington and Puget Sound VA Hospital
Associate Professor of Urology and Director of the Comprehensive Metabolic Stone Clinic
Dr. Brian Eisner, MD
Harvard Medical School – Assistant Professor of Surgery
MassGeneral – Co-Director, Kidney Stone Program
Dr. Ben Chew, MD
University of British Columbia – Associate Prof. of Urology
Vancouver General Hospital – Director of Clinical Research at the Stone Centre
Michael Bailey, PhD
University of Washington, Seattle
Faculty in Mechanical Engineering and Urology,
Senior Principal Engineer at the Applied Physics Lab and Program Director of NIH Program Projecton Lithotripsy
Barbrina Dunmire, MS
University of Washington, Seattle
Sr. Biomedical Engineer at Applied Physics Lab
Bryan Cunitz, MS
University of Washington, Seattle
Sr. Electrical Engineer at the Applied Physics Lab
Adam Maxwell, PhD
University of Washington, Seattle
Research Assistant Professor of Urology

Contact Us

SonoMotion Inc.

1600 West Hillsdale Boulevard, Suite 105
San Mateo, CA 94402

Dr. Oren Levy, CEO
Email: info@sonomotion.com